Last reviewed · How we verify

LY450139 — Competitive Intelligence Brief

LY450139 (LY450139) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Gamma-secretase inhibitor. Area: Neurology.

phase 3 Gamma-secretase inhibitor Gamma-secretase Neurology Small molecule Live · refreshed every 30 min

Target snapshot

LY450139 (LY450139) — Eli Lilly and Company. LY450139 is a gamma-secretase inhibitor that reduces the production of amyloid-beta by blocking the cleavage of amyloid precursor protein.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
LY450139 TARGET LY450139 Eli Lilly and Company phase 3 Gamma-secretase inhibitor Gamma-secretase
Nirogacestat oral tablet Nirogacestat oral tablet SpringWorks Therapeutics, Inc. phase 3 Gamma-secretase inhibitor Gamma-secretase complex (PSEN1/PSEN2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Gamma-secretase inhibitor class)

  1. Eli Lilly and Company · 1 drug in this class
  2. SpringWorks Therapeutics, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). LY450139 — Competitive Intelligence Brief. https://druglandscape.com/ci/ly450139. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: